Guide issued for off-label use of antipsychotics
The guide evaluates the use of Abilify, Zyprexa, Seroquel, Risperdal, and Geodon.
A new publication from AHRQ outlines the latest scientific evidence on off-label uses of atypical antipsychotics. The guide evaluates the use of aripiprazole (Abilify, Otsuka), olanzapine (Zyprexa, Lilly), quetiapine (Seroquel, AstraZeneca), risperidone (Risperdal, Janssen), and ziprasidone (Geodon, Pfizer), which are officially approved for treating schizophrenia and bipolar disorder but are often used off-label for conditions such as obsessive-compulsive disorder, dementia-related behavioral disturbances, agitation, anxiety, and psychotic episodes. The guide is the newest publication from the AHRQ Effective Health Care program and can be accessed on-line at
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
